Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.

Croteau, David; Tobenkin, Anne; Brinker, Allen; Kortepeter, Cindy M

Croteau, David; Tobenkin, Anne; Brinker, Allen; Kortepeter, Cindy M.

Afiliación

Croteau D; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food & Drug Administration, Silver Spring, MD, USA.
Tobenkin A; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food & Drug Administration, Silver Spring, MD, USA.
Brinker A; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food & Drug Administration, Silver Spring, MD, USA.
Kortepeter CM; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food & Drug Administration, Silver Spring, MD, USA.

Mult Scler ; 27(6): 903-912, 2021 05.

Article en En | MEDLINE | ID: mdl-32662718

Asunto(s)

Esclerosis Múltiple Recurrente-Remitente; Esclerosis Múltiple; Cognición; Clorhidrato de Fingolimod/efectos adversos; Humanos; Inmunosupresores/efectos adversos; Esclerosis Múltiple/tratamiento farmacológico; Recurrencia

Palabras clave

Fingolimod; S1P receptor modulator; multiple sclerosis; tumefactive demyelination

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google